Focusing on the development and commercialisation of neurological solutions
Exclusive worldwide licence
Extensive preclinical studies completed
Neurotech’s Mente device and therapy
World’s first whole plant extract cannabis clinical study
Potential for NTI164 to treat neurological disorders
PTC Patents lodged
Neurotech is a biopharmaceutical company focused on the development & commercialisation of neurological solutions that improve quality of life. NTI’s current focus is their world-first clinical study utilising NTI164 in the treatment for paediatric Autism Spectrum Disorder (ASD).
The Company is also focused on commercialising Mente, the world’s first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated Delta band brain activity.
Neurotech International (NTI: $0.071) has released the results from its Phase II study in children with moderate autismspectrumdisorder (ASD). The study involved 14 children who were treated with the proprietarymedicinal cannabis strain which contains less than 0.3% THC, which is the main psychoactive constituent of cannabis.